Quality Check,FDA

The landscape of compounded semaglutide is undergoing significant shifts due to increased FDA enforcement activity, particularly impacting compounding pharmacies. As of November 2025, these changes are designed to address concerns surrounding unapproved drugs and to ensure patient safety and product integrity. This article delves into the latest FDA policies, the rationale behind the enforcement, and what this means for both compounders and patients seeking compounded semaglutide and related GLP-1 medications.

The FDA has been actively clarifying its stance on compounded drugs, especially those that mirror the formulations of FDA-approved medications. A key development has been the removal of semaglutide from the national shortage list. For instance, the FDA removed semaglutide from its shortage list in February 2025. This change has significant implications, as it alters the conditions under which compounding pharmacies can produce these medications under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Following this delisting, many 503A pharmacies can no longer compound semaglutide injections unless specific exceptions, such as a valid and ongoing shortage or a unique medical need, are met.

This shift in policy has led to increased enforcement actions. The FDA has issued numerous warning letters to companies and compounders for unsubstantiated claims and the illegal sale of unapproved drugs. Specifically, in September 2025, the FDA issued over 50 warning letters to GLP-1 drug compounders and manufacturers, with some reports indicating over 55 such letters being sent. This proactive stance aims to curb the marketing of compounded products that are presented as identical to FDA-approved drugs, or that misrepresent their sourcing or efficacy. The FDA has specifically stated its objection to online claims that present compounded GLP-1s as effectively the same as the approved drug and to private label arrangements that circumvent regulatory oversight.

The FDA's enforcement actions are not arbitrary. The agency has expressed concerns about compounded drugs that are essentially copies of FDA-approved drugs, stating that such practices are no longer tolerated. This has led to a tightening of rules for compounding pharmacies. For example, bulk compounding of semaglutide and tirzepatide is no longer permitted because the FDA removed these products from the national shortage list. This regulatory evolution has been ongoing, with the FDA's moves to end the GLP-1 shortage and tighten 503A rules drawing significant public attention and comment between 2023 and 2025.

Furthermore, the FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, or retatrutide, particularly those falsely labeled "for research." This highlights a broader regulatory effort to ensure that all medications, whether FDA-approved or compounded, meet stringent safety and quality standards. The FDA intends to use all available compliance and enforcement tools to address these issues.

For patients, this means that accessing compounded semaglutide may become more challenging. While compounded semaglutide is still available in some capacity, the regulatory environment has made it more difficult to obtain, especially after the FDA declared the semaglutide shortage over. Some sources indicate that compounded semaglutide/tirzepatide will phase out by late May 2025, prompting a need for patients to transition to FDA-approved products.

The FDA's actions are part of a larger effort to ensure patient safety and regulatory compliance within the pharmaceutical industry. The agency has also issued warning letters to telehealth companies for alleged false or misleading marketing of compounded GLP-1s. This comprehensive approach underscores the FDA's commitment to safeguarding public health. As the FDA continues to clarify policies and escalate enforcement, stakeholders must remain informed about the evolving regulations surrounding compounded semaglutide and its therapeutic alternatives.

Key entities, LSI keywords, and variations integrated into the article:

* FDA

* enforcement

* 2025

* semaglutide

* Enforcement

* compounding

* Compounded Semaglutide and Tirzepatide Compliance Alert

* FDA bans compounded semaglutide

* Most 503A pharmacies can no longer compound semaglutide injections

* compounded

* Compounded semaglutide

* November

* compounded semaglutide

* Compounded

* compounding semaglutide

* Semaglutide

* GLP-1

* **tir